Glaukos Corporation is a healthcare company.
Glaukos Corporation (GKOS) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:10 ET. Consensus EPS estimate is $-0.12.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-29 | FY2026 Q2 | $-0.21 | $-0.31 | -47.2% | $185.61M |
| 2026-04-30 | FY2026 Q1 | $-0.30 | $-0.34 | -13.3% | $150.57M |
| 2025-10-29 | FY2025 Q3 | $-0.27 | $-0.28 | -3.7% | $133.54M |
| 2025-07-30 | FY2025 Q2 | $-0.26 | $-0.34 | -30.8% | $124.12M |
| 2025-05-01 | FY2025 Q1 | $-0.33 | $-0.32 | +3.0% | $106.66M |
| 2025-02-20 | FY2024 Q4 | $-0.38 | $-0.60 | -57.9% | $105.50M |
| 2024-11-05 | FY2024 Q3 | $-0.52 | $-0.39 | +25.0% | $96.67M |
| 2024-08-02 | FY2024 Q2 | $-0.52 | $-1.06 | -103.8% | $95.69M |
GKOS has beaten consensus EPS in 2 of its last 8 reported quarters.
GKOS reported Jul 29. The highlights: EPS of -$0.31 — a sharp miss vs the -$0.21 estimate (-47%); revenue of $186M — a big beat vs the $151M consensus (+23%). Focus now shifts to iDose ramp and reimbursement.
See GKOS on the live calendar →